Form 4: Lexicon Pharmaceuticals SVP Brian Corrigan Reports Stock Option and Restricted Stock Unit Grant

Brian Corrigan, SVP of Regulatory & QA at Lexicon Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• Brian Corrigan, SVP of Regulatory & QA at Lexicon Pharmaceuticals, filed a Form 4 on February 18, 2025, reporting transactions from February 13, 2025.
• Corrigan acquired 673,000 stock options with an exercise price of $0.695, vesting over time, and expiring on February 13, 2035.
• He also acquired 448,660 restricted stock units, each representing a contingent right to receive one share of common stock, vesting in three annual installments starting February 28 of each of the three years following the year of grant.
• Following these transactions, Corrigan directly owns 673,000 stock options and 448,660 restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and restricted stock units is a common practice and suggests confidence in the executive and the company's future.

Positives

• The grant of stock options and restricted stock units to a key executive like Brian Corrigan aligns his interests with those of the shareholders.
• The vesting schedules for both the options and restricted stock units incentivize long-term commitment and performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest a continued investment in key personnel.

Industry Context

Stock option and restricted stock unit grants are common compensation practices in the pharmaceutical industry to attract, retain, and incentivize key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, often used by companies like Amgen, Gilead Sciences, and Biogen.
• The vesting schedules described are typical, aligning with industry norms for incentivizing long-term performance and retention.
• The size of the grant would need to be compared to similar roles at comparable companies to determine if it is above or below industry averages.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align executive interests with company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Form 4, Lexicon Pharmaceuticals, Stock Options, Restricted Stock Units, Brian Corrigan, LXRX, SVP, Regulatory & QA, Beneficial Ownership